AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03509584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
Study NCT03517436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with CENTERA THV
Description: TAVR with the Edwards CENTERA THV System
Study NCT03271710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral balloon angioplasty
Description: Percutaneous transluminal angioplasty (PTA) of the lower extremities
Study NCT00109811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA:154-163(155L) peptide vaccine
Description: Given subcutaneously
Study NCT00109811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given subcutaneously
Study NCT00109811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02956655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting therapy
Description: The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
Study NCT02956655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)
Description: Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
Study NCT02956655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
Study NCT02956655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
Study NCT02956655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle guidance
Description: Lifestyle guidance is provided by specific physicians through phone calls
Study NCT02956655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle guidance
Description: Lifestyle guidance is provided by specific physicians through phone calls
Study NCT02956655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland
Study NCT04032366 — intervention group
Intervention type: DRUG
Intervention: inhaled nitric oxide
Description: using of inhaled nitric oxide
Study NCT04032366 — intervention group
Intervention type: DEVICE
Intervention: PEEP
Description: increasing PEEP or decreasing PEEP
Study NCT02594592 — intervention group
Intervention type: OTHER
Intervention: questionaire
Description: Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
Study NCT04549012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
Study NCT04549012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: One morphine sulfate 12mg IR capsule q6h
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl
Description: One oxycodone HCl 8mg IR Capsule q6h
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Q8003
Description: One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Two morphine sulfate 3mg IR capsules q6h
Study NCT00831051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone HCl 4mg
Description: Two oxycodone HCl 2mg IR Capsules q6h
Study NCT02366819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02366819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02366819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02366819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02366819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery
Study NCT04322708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04322708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study NCT03597906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topography guided ablation
Description: using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
Study NCT03325023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary and life style modification and probiotic Sanprobi Super Formula
Description: Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
Study NCT03325023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Zolbetuximab will be administered as a minimum 2-hour IV infusion.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.
Study NCT03509584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: administration of nivolumab
Study NCT03509584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: administration of ipilimumab
Study NCT02473744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subcutaneous drainage
Description: After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
Study NCT02381327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandometer
Description: Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
Study NCT01028391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
Description: Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
Study NCT01028391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
Study NCT01028391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
Study NCT01028391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
Study NCT03457584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: air arm
Description: epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
Study NCT03457584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BSS arm
Description: epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
Study NCT00033345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 400 mg pill taken daily
Study NCT00033345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indole-3-carbinol
Description: 800 mg pill taken daily
Study NCT03597906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manifest refraction
Description: using for ablation the exact manifest refraction
Study NCT03597906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full topography modified refraction
Description: full topography modified refraction means changing both sphere and cylinder power in the ablation profile
Study NCT03597906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial topography modified refraction
Description: partial topography modified refraction means changing only cylinder power and axis in the ablation profile
Study NCT00709592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO
Study NCT03866551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve Cardiovascular System
Description: The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
Study NCT00921921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Description: HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
Study NCT00921921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
Study NCT00746538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent
Description: Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study NCT00746538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Functional Assessment of HIV Infection
Description: Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Patient Satisfaction Questionnaire
Description: Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Symptom Distress Module
Description: Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Patient Health Questionnaire
Description: Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Internalized Stigma of AIDS Tool
Description: Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
Study NCT03400293 — intervention group
Intervention type: OTHER
Intervention: Medication adherence visual analogue scale
Description: Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
Study NCT00553787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 15 mg and topiramate 92 mg, po once daily
Study NCT00553787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily
Study NCT00553787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VI-0521
Description: placebo
Study NCT02039154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and strength training group
Description: A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
Study NCT02039154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and flexibility group
Description: For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
Study NCT03927040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MemorEM 1000
Description: The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
Study NCT03482661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetic steering
Description: The capsule was controlled to pass through the pylorus by magnet steering.
Study NCT02631187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bielefeld balloon
Description: Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
Study NCT02146846 — intervention group
Intervention type: DRUG
Intervention: Imatinib
Description: Patients with chronic myeloid leukemia who receive Imatinib as treatment
Study NCT02111369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
Study NCT02111369 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
Study NCT03431948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg given by intravenous infusion every 2 weeks
Study NCT03431948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
Study NCT03431948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Description: Urelumab 8 mg given by intravenous infusion every 4 weeks
Study NCT03431948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
Study NCT02404506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Description: Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
Study NCT02739139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaBrain
Description: Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
Study NCT02739139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AlphaBrain
Description: Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
Study NCT01813487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HBsAg vaccine with Entecavir
Study NCT01750918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Leucovorin will be administered as a 2-hour IV infusion.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folnic acid will be administered as a 2-hour IV infusion.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab will be administered intravenously according to institutional standards.
Study NCT03505320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as a 1-hour IV infusion.
Study NCT03272698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Ketamine 0.50 mg/kg
Study NCT03272698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV Ketamine 0.50 mg/kg
Study NCT03272698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
Study NCT00709592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01450280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Description: ChAd63 CS 5x10\^9 vp intra-muscularly Day 0
Study NCT01450280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS, MVA CS
Description: ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
Study NCT01450280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Description: ChAd63 CS 5x10\^10 vp intra-muscularly Day 0
Study NCT01450280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63, MVA CS
Description: ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
Study NCT00079443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00079443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00079443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV